Ojvind Davidsson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10807991/publications.pdf

Version: 2024-02-01

31	841	17 h-index	28
papers	citations		g-index
33	33	33	615
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Use of Small-Molecule Crystal Structures To Address Solubility in a Novel Series of G Protein Coupled Receptor 119 Agonists: Optimization of a Lead and in Vivo Evaluation. Journal of Medicinal Chemistry, 2012, 55, 5361-5379.	6.4	65
2	Toward Solution-State Structure. A 6Li,1H HOESY NMR, X-ray Diffraction, Semiempirical (PM3, MNDO), and ab Initio Computational Study of a Chiral Lithium Amide. Journal of the American Chemical Society, 1998, 120, 8143-8149.	13.7	63
3	Solution structure of a key intermediate used in asymmetric alkylation reactions. 1H, 1H-NOESY and 6Li, 1H-HOESY studies of mixtures of a chiral lithium amide and n-butyllithium. Journal of Organometallic Chemistry, 1995, 489, 175-179.	1.8	62
4	Chiral Lithium Amide/Solute Complexes:Â X-ray Crystallographic and NMR Spectroscopic Studies. Organometallics, 1997, 16, 3352-3362.	2.3	51
5	Rational Design of Chiral Lithium Amides for Asymmetric Alkylation Reactions-NMR Spectroscopic Studies of Mixed Lithium Amide/Alkyllithium Complexes. Chemistry - A European Journal, 1999, 5, 2348-2355.	3.3	48
6	The Use of 15N NMR Spectroscopy To Resolve the "Higher Order Cyanocuprate―Controversy:15N,6Li, and 13C NMR Spectroscopic Investigations of CuCN-Derived Butyl Cuprates. Angewandte Chemie - International Edition, 1998, 37, 314-317.	13.8	47
7	Enantioselective butylation of aliphatic aldehydes by mixed chiral lithium amide/n-BuLi dimers. Tetrahedron: Asymmetry, 1999, 10, 527-534.	1.8	41
8	Recent advances for FLAP inhibitors. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 2607-2612.	2,2	40
9	Discovery of AZD6642, an Inhibitor of 5-Lipoxygenase Activating Protein (FLAP) for the Treatment of Inflammatory Diseases. Journal of Medicinal Chemistry, 2015, 58, 897-911.	6.4	39
10	A Novel Mixed Dimer of a Norephedrine-Derived Chiral Lithium Amide and 2-Lithium-1-methylimidazole, and Catalytic Enantioselective Deprotonation of Cyclohexene Oxide. Chemistry - A European Journal, 2001, 7, 4368-4377.	3.3	38
11	Solution Structure of a Dilithiumamide/Diethylzinc Heterocomplex that Catalyzes Asymmetric Alkylation Reactions. Chemistry - A European Journal, 1999, 5, 2356-2361.	3.3	36
12	6Li and 15N NMR Data as a Probe for the Influence of Solvent and Intramolecular Solvation on the Solution-State Structures of Chiral Lithium Amides. Angewandte Chemie - International Edition, 2000, 39, 1467-1470.	13.8	35
13	Enantiomeric Perturbation of Equilibria. Differential Solvation of a Chiral Lithium Amide by the Enantiomers of 2-Methyltetrahydrofuran Measured by NMR Spectroscopy. Journal of the American Chemical Society, 1996, 118, 3539-3540.	13.7	24
14	Internal coordination and solvent effects upon hetero- and homocomplexation of chiral lithium amides: structure reactivity effects. Journal of Organometallic Chemistry, 2000, 608, 153-163.	1.8	22
15	Solid-phase supported chiral lithium amides used in deprotonation reactions. Tetrahedron: Asymmetry, 2003, 14, 1261-1266.	1.8	22
16	Isoindolinone compounds active as Kv1.5 blockers identified using a multicomponent reaction approach. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 2023-2029.	2.2	18
17	The Structure of a Chiral Lithium Amidocuprate in Solution Determined by Multinuclear NMR Spectroscopy. Journal of the American Chemical Society, 2000, 122, 9310-9311.	13.7	17
18	On the Mechanism of Internal ortho-Lithiation in a Mixed Complex Between BuLi and a Chiral Lithium Amide. Helvetica Chimica Acta, 2002, 85, 3814-3822.	1.6	16

#	Article	IF	Citations
19	Discovery, optimisation and in vivo evaluation of novel GPR119 agonists. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 7310-7316.	2.2	15
20	Evidence for a Lithium Amidocuprate/Cyclohexenone Complex in Solution. Organometallics, 2001, 20, 4763-4765.	2.3	14
21	Homo- and Heterocomplexes of Sodium and Lithium Amidesâ€"Structures in Solution. Chemistry - A European Journal, 2001, 7, 3461.	3.3	14
22	Structure of [1.1]Ferrocenophanyllithium in the Solution and the Solid State. Absence of an Intramolecular [Câ^'Hâ^'C]- Hydrogen Bond. Journal of the American Chemical Society, 1997, 119, 1745-1750.	13.7	13
23	Chelate Ring Size Controls the Formation of Mixed Complexes Involving Butyllithium and Sodium Amides. Organometallics, 2002, 21, 2283-2292.	2.3	11
24	Asymmetry of the first directly observed intramolecular $[C\hat{a}\in H\hat{a}\in G]\hat{a}\in hydrogen$ bond in the carbanion of $[1.1]$ ferrocenophane demonstrated by dynamic n.m.r. spectroscopy. Journal of the Chemical Society Chemical Communications, 1987, , 623-624.	2.0	10
25	Crystal structure of ferrocenophanyllithium: absence of an intramolecular C–H â√–C hydrogen bond. Journal of the Chemical Society Chemical Communications, 1994, , 1573-1574.	2.0	10
26	Formation of Heterodimer Complexes between Analogous Chiral Lithium Amides:  NMR Spectroscopic and Computational Studies. Organometallics, 2001, 20, 4185-4189.	2.3	10
27	Mechanism and Solvent Catalysis of the Degenerate $1,12$ -Metalations of $[1.1]$ Ferrocenophanyllithium and $[1.1]$ Ferrocenophanylsodium Studied by NMR Spectroscopy. Journal of the American Chemical Society, 1997, 119, 1751-1757.	13.7	9
28	Lactam sulfonamides as potent inhibitors of the Kv1.5 potassium ion channel. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 1269-1273.	2.2	9
29	Monomeric †benzyl lithium' in 2,5-dimethyltetrahydrofuran. NMR spectroscopic studies of6Li and13C2labelled ferrocenophanyl lithium using13C†6Li coupling and6Li decoupling. Journal of the Chemical Society Chemical Communications, 1992, .	2.0	6
30	[1.1]Ferrocenophanes in solution?Anti orsyn isomers?. Journal of Physical Organic Chemistry, 1996, 9, 436-438.	1.9	5
31	Identification of novel GPR81 agonist lead series for target biology evaluation. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 126953.	2.2	5